{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:19:02Z","timestamp":1791919142801,"version":"4.3.4"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2010,7,27]],"date-time":"2010-07-27T00:00:00Z","timestamp":1280188800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1038\/nrendo.2010.122","type":"journal-article","created":{"date-parts":[[2010,7,27]],"date-time":"2010-07-27T15:05:05Z","timestamp":1280243105000},"page":"494-508","source":"Crossref","is-referenced-by-count":45,"title":["Effect of systemic medications on onset and progression of diabetic retinopathy"],"prefix":"10.1038","volume":"6","author":[{"given":"Paolo S.","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry D.","family":"Cavallerano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd M.","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd Paul","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,7,27]]},"reference":[{"key":"BFnrendo2010122_CR1","doi-asserted-by":"crossref","unstructured":"[No authors listed] Standards of medical care in diabetes-\u20142010. Diabetes Care 33 (Suppl. 1) S11\u2013S61 (2010).","DOI":"10.2337\/dc10-S011"},{"key":"BFnrendo2010122_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.diabres.2009.11.006","volume":"87","author":"N Unwin","year":"2010","unstructured":"Unwin, N., Gan, D. & Whiting, D. The IDF Diabetes Atlas: Providing evidence, raising awareness and promoting action. Diabetes Res. Clin. Pract. 87, 2\u20133 (2010).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"BFnrendo2010122_CR3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.diabres.2009.08.012","volume":"86","author":"S Ioacara","year":"2009","unstructured":"Ioacara, S.  et al. Improvements in life expectancy in type 1 diabetes patients in the last six decades. Diabetes Res. Clin. Pract. 86, 146\u2013151 (2009).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"BFnrendo2010122_CR4","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.2337\/dc06-2222","volume":"30","author":"HA Keenan","year":"2007","unstructured":"Keenan, H. A.  et al. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. Diabetes Care 30, 1995\u20131997 (2007).","journal-title":"Diabetes Care"},{"key":"BFnrendo2010122_CR5","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1046\/j.1464-5491.2003.01029.x","volume":"20","author":"SC Bain","year":"2003","unstructured":"Bain, S. C.  et al. Characteristics of type 1 diabetes of over 50 years duration (the Golden Years Cohort). Diabet. Med. 20, 808\u2013811 (2003).","journal-title":"Diabet. Med."},{"key":"BFnrendo2010122_CR6","unstructured":"Centers for Disease Control and Prevention. National diabetes fact sheet: General information and national estimates on diabetes in the United States \n                    [online]\n                    \n                  , (2007)."},{"key":"BFnrendo2010122_CR7","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/j.1464-5491.2007.02180.x","volume":"24","author":"R Luckie","year":"2007","unstructured":"Luckie, R.  et al. Fear of visual loss in patients with diabetes: results of the prevalence of diabetic eye disease in Tayside, Scotland (P-DETS) study. Diabet. Med. 24, 1086\u20131092 (2007).","journal-title":"Diabet. Med."},{"key":"BFnrendo2010122_CR8","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1001\/archopht.122.4.552","volume":"122","author":"JH Kempen","year":"2004","unstructured":"Kempen, J. H.  et al. The prevalence of diabetic retinopathy among adults in the United States. Arch. Ophthalmol. 122, 552\u2013563 (2004).","journal-title":"Arch. Ophthalmol."},{"key":"BFnrendo2010122_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJM198801213180303","volume":"318","author":"AS Krolewski","year":"1988","unstructured":"Krolewski, A. S.  et al. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N. Engl. J. Med. 318, 140\u2013145 (1988).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2010122_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0168-8227(97)01386-7","volume":"35","author":"CD Agardh","year":"1997","unstructured":"Agardh, C. D., Agardh, E. & Torffvit, O. The association between retinopathy, nephropathy, cardiovascular disease and long-term metabolic control in type 1 diabetes mellitus: a 5 year follow-up study of 442 adult patients in routine care. Diabetes Res. Clin. Pract. 35, 113\u2013121 (1997).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"BFnrendo2010122_CR11","first-page":"131","volume":"2","author":"LJ Alexander","year":"1992","unstructured":"Alexander, L. J., Cavallerano, J., Schwartz, G. L. & Zimmerman, B. R. Co-management of patients with hypertension or diabetes. Optom. Clin. 2, 131\u2013142 (1992).","journal-title":"Optom. Clin."},{"key":"BFnrendo2010122_CR12","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0161-6420(13)31517-6","volume":"100","author":"G Marshall","year":"1993","unstructured":"Marshall, G., Garg, S. K., Jackson, W. E., Holmes, D. L. & Chase, H. P. Factors influencing the onset and progression of diabetic retinopathy in subjects with insulin-dependent diabetes mellitus. Ophthalmology 100, 1133\u20131139 (1993).","journal-title":"Ophthalmology"},{"key":"BFnrendo2010122_CR13","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0002-9394(01)01124-2","volume":"132","author":"LP Aiello","year":"2001","unstructured":"Aiello, L. P., Cahill, M. T. & Wong, J. S. Systemic considerations in the management of diabetic retinopathy. Am. J. Ophthalmol. 132, 760\u2013776 (2001).","journal-title":"Am. J. Ophthalmol."},{"key":"BFnrendo2010122_CR14","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1056\/NEJM197304192881609","volume":"288","author":"KH Gabbay","year":"1973","unstructured":"Gabbay, K. H. The sorbitol pathway and the complications of diabetes. N. Engl. J. Med. 288, 831\u2013836 (1973).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2010122_CR15","doi-asserted-by":"publisher","first-page":"527","DOI":"10.7326\/0003-4819-101-4-527","volume":"101","author":"M Brownlee","year":"1984","unstructured":"Brownlee, M., Vlassara, H. & Cerami, A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann. Intern. Med. 101, 527\u2013537 (1984).","journal-title":"Ann. Intern. Med."},{"key":"BFnrendo2010122_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0083-6729(00)60019-5","volume":"60","author":"DK Ways","year":"2000","unstructured":"Ways, D. K. & Sheetz, M. J. The role of protein kinase C in the development of the complications of diabetes. Vitam. Horm. 60, 149\u2013193 (2000).","journal-title":"Vitam. Horm."},{"key":"BFnrendo2010122_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/diabetes.48.1.1","volume":"48","author":"JW Baynes","year":"1999","unstructured":"Baynes, J. W. & Thorpe, S. R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48, 1\u20139 (1999).","journal-title":"Diabetes"},{"key":"BFnrendo2010122_CR18","doi-asserted-by":"publisher","first-page":"95103","DOI":"10.1155\/2007\/95103","volume":"2007","author":"TS Kern","year":"2007","unstructured":"Kern, T. S. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp. Diabetes Res. 2007, 95103 (2007).","journal-title":"Exp. Diabetes Res."},{"key":"BFnrendo2010122_CR19","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2337\/diab.39.5.602","volume":"39","author":"JE Grunwald","year":"1990","unstructured":"Grunwald, J. E.  et al. Diabetic glycemic control and retinal blood flow. Diabetes 39, 602\u2013607 (1990).","journal-title":"Diabetes"},{"key":"BFnrendo2010122_CR20","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello, L. P.  et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331, 1480\u20131487 (1994).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2010122_CR21","doi-asserted-by":"publisher","first-page":"23463","DOI":"10.1074\/jbc.274.33.23463","volume":"274","author":"DA Antonetti","year":"1999","unstructured":"Antonetti, D. A., Barber, A. J., Hollinger, L. A., Wolpert, E. B. & Gardner, T. W. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J. Biol. Chem. 274, 23463\u201323467 (1999).","journal-title":"J. Biol. Chem."},{"key":"BFnrendo2010122_CR22","doi-asserted-by":"crossref","unstructured":"[No authors listed] Four risk factors for severe visual loss in diabetic retinopathy. The third report from the Diabetic Retinopathy Study. The Diabetic Retinopathy Study Research Group. Arch. Ophthalmol. 97, 654\u2013655 (1979).","DOI":"10.1001\/archopht.1979.01020010310003"},{"key":"BFnrendo2010122_CR23","doi-asserted-by":"crossref","unstructured":"[No authors listed] Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch. Ophthalmol. 103, 1796\u20131806 (1985).","DOI":"10.1001\/archopht.1985.01050120030015"},{"issue":"Suppl. 3","key":"BFnrendo2010122_CR24","doi-asserted-by":"publisher","first-page":"C35","DOI":"10.2337\/diacare.21.3.C35","volume":"21","author":"RC Turner","year":"1998","unstructured":"Turner, R. C. The U.K. Prospective Diabetes Study. A review. Diabetes Care 21 (Suppl. 3) C35\u2013C38 (1998).","journal-title":"Diabetes Care"},{"key":"BFnrendo2010122_CR25","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","volume":"370","author":"AC Keech","year":"2007","unstructured":"Keech, A. C.  et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370, 1687\u20131697 (2007).","journal-title":"Lancet"},{"key":"BFnrendo2010122_CR26","doi-asserted-by":"crossref","unstructured":"[No authors listed] Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 22, 99\u2013111 (1999).","DOI":"10.2337\/diacare.22.1.99"},{"key":"BFnrendo2010122_CR27","doi-asserted-by":"crossref","unstructured":"[No authors listed] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837\u2013853 (1998).","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"BFnrendo2010122_CR28","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S0161-6420(97)30327-3","volume":"104","author":"AK Sj\u00f8lie","year":"1997","unstructured":"Sj\u00f8lie, A. K.  et al. Retinopathy and vision loss in insulin-dependent diabetes in Europe. The EURODIAB IDDM Complications Study. Ophthalmology 104, 252\u2013260 (1997).","journal-title":"Ophthalmology"},{"key":"BFnrendo2010122_CR29","doi-asserted-by":"crossref","unstructured":"[No authors listed] Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317, 703\u2013713 (1998).","DOI":"10.1136\/bmj.317.7160.703"},{"key":"BFnrendo2010122_CR30","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1001\/archopht.126.12.1707","volume":"126","author":"NH White","year":"2008","unstructured":"White, N. H.  et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch. Ophthalmol. 126, 1707\u20131715 (2008).","journal-title":"Arch. Ophthalmol."},{"key":"BFnrendo2010122_CR31","doi-asserted-by":"crossref","unstructured":"[No authors listed] Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287, 2563\u20132569 (2002).","DOI":"10.1001\/jama.287.19.2563"},{"key":"BFnrendo2010122_CR32","doi-asserted-by":"crossref","unstructured":"[No authors listed] The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch. Ophthalmol. 113, 36\u201351 (1995).","DOI":"10.1001\/archopht.1995.01100010038019"},{"key":"BFnrendo2010122_CR33","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/j.ophtha.2008.08.023","volume":"115","author":"R Klein","year":"2008","unstructured":"Klein, R., Knudtson, M. D., Lee, K. E., Gangnon, R. & Klein, B. E. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 115, 1859\u20131868 (2008).","journal-title":"Ophthalmology"},{"key":"BFnrendo2010122_CR34","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R. & Neil, H. A. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577\u20131589 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2010122_CR35","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2174\/187152907782793581","volume":"7","author":"G Anfossi","year":"2007","unstructured":"Anfossi, G., Russo, I., Doronzo, G. & Trovati, M. Relevance of the vascular effects of insulin in the rationale of its therapeutical use. Cardiovasc. Hematol. Disord. Drug Targets. 7, 228\u2013249 (2007).","journal-title":"Cardiovasc. Hematol. Disord. Drug Targets."},{"key":"BFnrendo2010122_CR36","first-page":"3281","volume":"40","author":"M Lu","year":"1999","unstructured":"Lu, M.  et al. Insulin-induced vascular endothelial growth factor expression in retina. Invest. Ophthalmol. Vis. Sci. 40, 3281\u20133286 (1999).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"BFnrendo2010122_CR37","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1172\/JCI0213776","volume":"109","author":"V Poulaki","year":"2002","unstructured":"Poulaki, V.  et al. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J. Clin. Invest. 109, 805\u2013815 (2002).","journal-title":"J. Clin. Invest."},{"key":"BFnrendo2010122_CR38","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0002-9394(14)75794-0","volume":"118","author":"AP Adamis","year":"1994","unstructured":"Adamis, A. P.  et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118, 445\u2013450 (1994).","journal-title":"Am. J. Ophthalmol."},{"key":"BFnrendo2010122_CR39","doi-asserted-by":"crossref","unstructured":"[No authors listed] Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch. Ophthalmol. 116, 874\u2013886 (1998).","DOI":"10.1001\/archopht.116.7.874"},{"key":"BFnrendo2010122_CR40","doi-asserted-by":"crossref","unstructured":"[No authors listed] Blood glucose control and the evolution of diabetic retinopathy and albuminuria. A preliminary multicenter trial. The Kroc Collaborative Study Group. N. Engl. J. Med. 311, 365\u2013372 (1984).","DOI":"10.1056\/NEJM198408093110604"},{"key":"BFnrendo2010122_CR41","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(83)92585-0","volume":"1","author":"T Lauritzen","year":"1983","unstructured":"Lauritzen, T., Frost-Larsen, K., Larsen, H. W. & Deckert, T. Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. Lancet 1, 200\u2013204 (1983).","journal-title":"Lancet"},{"key":"BFnrendo2010122_CR42","first-page":"356","volume":"36","author":"H Funatsu","year":"1992","unstructured":"Funatsu, H., Yamashita, H., Ohashi, Y. & Ishigaki, T. Effect of rapid glycemic control on progression of diabetic retinopathy. Jpn. J. Ophthalmol. 36, 356\u2013367 (1992).","journal-title":"Jpn. J. Ophthalmol."},{"key":"BFnrendo2010122_CR43","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/1056-8727(92)90018-G","volume":"6","author":"CD Agardh","year":"1992","unstructured":"Agardh, C. D., Eckert, B. & Agardh, E. Irreversible progression of severe retinopathy in young type I insulin-dependent diabetes mellitus patients after improved metabolic control. J. Diabetes Complications 6, 96\u2013100 (1992).","journal-title":"J. Diabetes Complications"},{"key":"BFnrendo2010122_CR44","first-page":"985","volume":"24","author":"JT Ernest","year":"1983","unstructured":"Ernest, J. T., Goldstick, T. K. & Engerman, R. L. Hyperglycemia impairs retinal oxygen autoregulation in normal and diabetic dogs. Invest. Ophthalmol. Vis. Sci. 24, 985\u2013989 (1983).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"BFnrendo2010122_CR45","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1136\/bjo.78.8.598","volume":"78","author":"JE Grunwald","year":"1994","unstructured":"Grunwald, J. E.  et al. Strict metabolic control and retinal blood flow in diabetes mellitus. Br. J. Ophthalmol. 78, 598\u2013604 (1994).","journal-title":"Br. J. Ophthalmol."},{"key":"BFnrendo2010122_CR46","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1177\/112067211002000133","volume":"20","author":"S Casati","year":"2010","unstructured":"Casati, S., Zoppini, G., Muggeo, M. & Marchini, G. Sustained regression of florid diabetic retinopathy in a patient with Donohue syndrome (leprechaunism). Eur. J. Ophthalmol. 20, 224\u2013227 (2010).","journal-title":"Eur. J. Ophthalmol."},{"key":"BFnrendo2010122_CR47","doi-asserted-by":"publisher","first-page":"360","DOI":"10.2337\/diacare.4.3.360","volume":"4","author":"D Daneman","year":"1981","unstructured":"Daneman, D.  et al. Progressive retinopathy with improved control in diabetic dwarfism (Mauriac's syndrome). Diabetes Care 4, 360\u2013365 (1981).","journal-title":"Diabetes Care"},{"key":"BFnrendo2010122_CR48","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2337\/diacare.24.4.631","volume":"24","author":"J Rosenstock","year":"2001","unstructured":"Rosenstock, J.  et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24, 631\u2013636 (2001).","journal-title":"Diabetes Care"},{"key":"BFnrendo2010122_CR49","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/ann.34.3.217.224","volume":"34","author":"M Stumvoll","year":"2002","unstructured":"Stumvoll, M. & H\u00e4ring, H. U. Glitazones: clinical effects and molecular mechanisms. Ann. Med. 34, 217\u2013224 (2002).","journal-title":"Ann. Med."},{"key":"BFnrendo2010122_CR50","doi-asserted-by":"publisher","first-page":"164273","DOI":"10.1155\/2008\/164273","volume":"2008","author":"HA Pershadsingh","year":"2008","unstructured":"Pershadsingh, H. A. & Moore, D. M. PPARgamma agonists: Potential as therapeutics for neovascular retinopathies. PPAR Res. 2008, 164273 (2008).","journal-title":"PPAR Res."},{"key":"BFnrendo2010122_CR51","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/archopht.126.6.793","volume":"126","author":"LQ Shen","year":"2008","unstructured":"Shen, L. Q., Child, A., Weber, G. M., Folkman, J. & Aiello, L. P. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch. Ophthalmol. 126, 793\u2013799 (2008).","journal-title":"Arch. Ophthalmol."},{"key":"BFnrendo2010122_CR52","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1172\/JCI0215634","volume":"110","author":"D Panigrahy","year":"2002","unstructured":"Panigrahy, D.  et al. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J. Clin. Invest. 110, 923\u2013932 (2002).","journal-title":"J. Clin. Invest."},{"key":"BFnrendo2010122_CR53","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen, S. E. & Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457\u20132471 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2010122_CR54","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1056\/NEJMoa073394","volume":"357","author":"PD Home","year":"2007","unstructured":"Home, P. D.  et al. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N. Engl. J. Med. 357, 28\u201338 (2007).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 8A","key":"BFnrendo2010122_CR55","doi-asserted-by":"publisher","first-page":"111S","DOI":"10.1016\/j.amjmed.2003.09.018","volume":"115","author":"NK Hollenberg","year":"2003","unstructured":"Hollenberg, N. K. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am. J. Med. 115 (Suppl. 8A) 111S\u2013115S (2003).","journal-title":"Am. J. Med."},{"key":"BFnrendo2010122_CR56","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1097\/00006982-200605000-00011","volume":"26","author":"EH Ryan Jr","year":"2006","unstructured":"Ryan, E. H. Jr  et al. Diabetic macular edema associated with glitazone use. Retina 26, 562\u2013570 (2006).","journal-title":"Retina"},{"key":"BFnrendo2010122_CR57","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ajo.2008.10.016","volume":"147","author":"DS Fong","year":"2009","unstructured":"Fong, D. S. & Contreras, R. Glitazone use associated with diabetic macular edema. Am. J. Ophthalmol. 147, 583\u2013586 (2009).","journal-title":"Am. J. Ophthalmol."},{"key":"BFnrendo2010122_CR58","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1001\/archophthalmol.2009.310","volume":"128","author":"WT Ambrosius","year":"2010","unstructured":"Ambrosius, W. T.  et al. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch. Ophthalmol. 128, 312\u2013318 (2010).","journal-title":"Arch. Ophthalmol."},{"key":"BFnrendo2010122_CR59","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.2337\/dc06-9912","volume":"29","author":"DM Nathan","year":"2006","unstructured":"Nathan, D. M.  et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29, 1963\u20131972 (2006).","journal-title":"Diabetes Care"},{"key":"BFnrendo2010122_CR60","doi-asserted-by":"crossref","unstructured":"[No authors listed] Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 854\u2013865 (1998).","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"BFnrendo2010122_CR61","first-page":"4059","volume":"81","author":"K Cusi","year":"1996","unstructured":"Cusi, K., Consoli, A. & DeFronzo, R. A. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 81, 4059\u20134067 (1996).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2010122_CR62","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2337\/diacare.16.4.621","volume":"16","author":"DK Nagi","year":"1993","unstructured":"Nagi, D. K. & Yudkin, J. S. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 16, 621\u2013629 (1993).","journal-title":"Diabetes Care"},{"key":"BFnrendo2010122_CR63","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.biopha.2009.08.004","volume":"64","author":"DO Xavier","year":"2010","unstructured":"Xavier, D. O.  et al. Metformin inhibits inflammatory angiogenesis in a murine sponge model. Biomed. Pharmacother. 64, 220\u2013225 (2010).","journal-title":"Biomed. Pharmacother."},{"key":"BFnrendo2010122_CR64","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/cvr\/cvp131","volume":"83","author":"BK Tan","year":"2009","unstructured":"Tan, B. K.  et al. Metformin decreases angiogenesis via NF-kappaB and Erk1\/2\/Erk5 pathways by increasing the antiangiogenic thrombospondin-1. Cardiovasc. Res. 83, 566\u2013574 (2009).","journal-title":"Cardiovasc. Res."},{"key":"BFnrendo2010122_CR65","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1096\/fj.02-0157fje","volume":"17","author":"AM Joussen","year":"2003","unstructured":"Joussen, A. M.  et al. Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. FASEB J. 17, 76\u201378 (2003).","journal-title":"FASEB J."},{"key":"BFnrendo2010122_CR66","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/archopht.1996.01100140281004","volume":"114","author":"EY Chew","year":"1996","unstructured":"Chew, E. Y.  et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch. Ophthalmol. 114, 1079\u20131084 (1996).","journal-title":"Arch. Ophthalmol."},{"key":"BFnrendo2010122_CR67","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S0161-6420(91)32145-6","volume":"98","author":"BE Klein","year":"1991","unstructured":"Klein, B. E., Moss, S. E., Klein, R. & Surawicz, T. S. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 98, 1261\u20131265 (1991).","journal-title":"Ophthalmology"},{"key":"BFnrendo2010122_CR68","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1167\/iovs.02-0648","volume":"45","author":"TJ Lyons","year":"2004","unstructured":"Lyons, T. J.  et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT\/EDIC cohort. Invest. Ophthalmol. Vis. Sci. 45, 910\u2013918 (2004).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"BFnrendo2010122_CR69","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2174\/138161209787315701","volume":"15","author":"JC Ansquer","year":"2009","unstructured":"Ansquer, J. C., Foucher, C., Aubonnet, P. & Le Malicot, K. Fibrates and microvascular complications in diabetes\u2014insight from the FIELD study. Curr. Pharm. Des. 15, 537\u2013552 (2009).","journal-title":"Curr. Pharm. Des."},{"key":"BFnrendo2010122_CR70","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1073\/pnas.0711281105","volume":"105","author":"D Panigrahy","year":"2008","unstructured":"Panigrahy, D.  et al. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc. Natl Acad. Sci. USA 105, 985\u2013990 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrendo2010122_CR71","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3109\/07853890008998823","volume":"32","author":"S Bellosta","year":"2000","unstructured":"Bellosta, S., Ferri, N., Bernini, F., Paoletti, R. & Corsini, A. Non-lipid-related effects of statins. Ann. Med. 32, 164\u2013176 (2000).","journal-title":"Ann. Med."},{"key":"BFnrendo2010122_CR72","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1096\/fj.03-0839rev","volume":"18","author":"FR Danesh","year":"2004","unstructured":"Danesh, F. R. & Kanwar, Y. S. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J. 18, 805\u2013815 (2004).","journal-title":"FASEB J."},{"key":"BFnrendo2010122_CR73","doi-asserted-by":"publisher","first-page":"458","DOI":"10.2337\/diab.17.7.458","volume":"17","author":"LJ Duncan","year":"1968","unstructured":"Duncan, L. J.  et al. A three-year trial of atromid therapy in exudative diabetic retinopathy. Diabetes 17, 458\u2013467 (1968).","journal-title":"Diabetes"},{"key":"BFnrendo2010122_CR74","first-page":"554","volume":"94","author":"JF Cullen","year":"1974","unstructured":"Cullen, J. F., Town, S. M. & Campbell, C. J. Double-blind trial of Atromid-S in exudative diabetic retinopathy. Trans. Ophthalmol. Soc. UK 94, 554\u2013562 (1974).","journal-title":"Trans. Ophthalmol. Soc. UK"},{"key":"BFnrendo2010122_CR75","first-page":"281","volume":"84","author":"JF Cullen","year":"1964","unstructured":"Cullen, J. F., Ireland, J. T. & Oliver, M. F. A controlled trial of Atromid therapy in exudative diabetic retinopathy. Trans. Ophthalmol. Soc. UK 84, 281\u2013295 (1964).","journal-title":"Trans. Ophthalmol. Soc. UK"},{"key":"BFnrendo2010122_CR76","first-page":"594","volume":"89","author":"H Freyberger","year":"1994","unstructured":"Freyberger, H., Schifferdecker, E. & Schatz, H. [Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent]. Med. Klin. (Munich) 89, 594\u2013597, 633 (1994).","journal-title":"Med. Klin. (Munich)"},{"key":"BFnrendo2010122_CR77","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1055\/s-0028-1109516","volume":"226","author":"KH Emmerich","year":"2009","unstructured":"Emmerich, K. H.  et al. [Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy]. Klin. Monbl. Augenheilkd. 226, 561\u2013567 (2009).","journal-title":"Klin. Monbl. Augenheilkd."},{"key":"BFnrendo2010122_CR78","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrendo.2009.213","volume":"6","author":"P Fioretto","year":"2010","unstructured":"Fioretto, P., Dodson, P. M., Ziegler, D. & Rosenson, R. S. Residual microvascular risk in diabetes: unmet needs and future directions. Nat. Rev. Endocrinol. 6, 19\u201325 (2010).","journal-title":"Nat. Rev. Endocrinol."},{"key":"BFnrendo2010122_CR79","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1056\/NEJMoa021778","volume":"348","author":"P Gaede","year":"2003","unstructured":"Gaede, P.  et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348, 383\u2013393 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2010122_CR80","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"HM Colhoun","year":"2004","unstructured":"Colhoun, H. M.  et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364, 685\u2013696 (2004).","journal-title":"Lancet"},{"key":"BFnrendo2010122_CR81","doi-asserted-by":"publisher","first-page":"103i","DOI":"10.1016\/j.amjcard.2007.03.028","volume":"99","author":"EY Chew","year":"2007","unstructured":"Chew, E. Y.  et al. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). Am. J. Cardiol. 99, 103i\u2013111i (2007).","journal-title":"Am. J. Cardiol."},{"key":"BFnrendo2010122_CR82","doi-asserted-by":"crossref","unstructured":"The ACCORD Study Group and ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N. Engl. J. Med. doi: 10.1056\/NEJMoa1001288.","DOI":"10.1056\/NEJMoa1001288"},{"key":"BFnrendo2010122_CR83","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.biocel.2005.08.002","volume":"38","author":"JL Wilkinson-Berka","year":"2006","unstructured":"Wilkinson-Berka, J. L. Angiotensin and diabetic retinopathy. Int. J. Biochem. Cell Biol. 38, 752\u2013765 (2006).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"BFnrendo2010122_CR84","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1136\/bjo.80.2.159","volume":"80","author":"J Wagner","year":"1996","unstructured":"Wagner, J.  et al. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br. J. Ophthalmol. 80, 159\u2013163 (1996).","journal-title":"Br. J. Ophthalmol."},{"key":"BFnrendo2010122_CR85","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S0002-9440(10)63448-7","volume":"163","author":"S Sarlos","year":"2003","unstructured":"Sarlos, S.  et al. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am. J. Pathol. 163, 879\u2013887 (2003).","journal-title":"Am. J. Pathol."},{"key":"BFnrendo2010122_CR86","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1001\/archophthalmol.2009.391","volume":"128","author":"R Klein","year":"2010","unstructured":"Klein, R.  et al. Relationship of blood pressure to retinal vessel diameter in type 1 diabetes mellitus. Arch. Ophthalmol. 128, 198\u2013205 (2010).","journal-title":"Arch. Ophthalmol."},{"key":"BFnrendo2010122_CR87","doi-asserted-by":"crossref","unstructured":"[No authors listed] Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 317, 713\u2013720 (1998).","DOI":"10.1136\/bmj.317.7160.713"},{"key":"BFnrendo2010122_CR88","doi-asserted-by":"crossref","unstructured":"[No authors listed] Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317, 703\u2013713 (1998).","DOI":"10.1136\/bmj.317.7160.703"},{"key":"BFnrendo2010122_CR89","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S0140-6736(97)06209-0","volume":"351","author":"N Chaturvedi","year":"1998","unstructured":"Chaturvedi, N.  et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 351, 28\u201331 (1998).","journal-title":"Lancet"},{"key":"BFnrendo2010122_CR90","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","volume":"370","author":"A Patel","year":"2007","unstructured":"Patel, A.  et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370, 829\u2013840 (2007).","journal-title":"Lancet"},{"key":"BFnrendo2010122_CR91","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1056\/NEJMoa0808400","volume":"361","author":"M Mauer","year":"2009","unstructured":"Mauer, M.  et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N. Engl. J. Med. 361, 40\u201351 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2010122_CR92","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0140-6736(08)61411-7","volume":"372","author":"AK Sj\u00f8lie","year":"2008","unstructured":"Sj\u00f8lie, A. K.  et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 372, 1385\u20131393 (2008).","journal-title":"Lancet"},{"key":"BFnrendo2010122_CR93","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/S0140-6736(08)61412-9","volume":"372","author":"N Chaturvedi","year":"2008","unstructured":"Chaturvedi, N.  et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 372, 1394\u20131402 (2008).","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"BFnrendo2010122_CR94","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/0026-0495(79)90044-1","volume":"28","author":"JA Colwell","year":"1979","unstructured":"Colwell, J. A.  et al. Platelet adhesion and aggregation in diabetes mellitus. Metabolism 28 (Suppl. 1) 394\u2013400 (1979).","journal-title":"Metabolism"},{"key":"BFnrendo2010122_CR95","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.2337\/diabetes.50.6.1432","volume":"50","author":"D Boeri","year":"2001","unstructured":"Boeri, D., Maiello, M. & Lorenzi, M. Increased prevalence of microthromboses in retinal capillaries of diabetic individuals. Diabetes 50, 1432\u20131439 (2001).","journal-title":"Diabetes"},{"key":"BFnrendo2010122_CR96","doi-asserted-by":"crossref","unstructured":"[No authors listed] Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 98, 757\u2013765 (1991).","DOI":"10.1016\/S0161-6420(13)38010-5"},{"key":"BFnrendo2010122_CR97","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/archopht.1995.01100010054020","volume":"113","author":"EY Chew","year":"1995","unstructured":"Chew, E. Y., Klein, M. L., Murphy, R. P., Remaley, N. A. & Ferris, F. L. III. Effects of aspirin on vitreous\/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Arch. Ophthalmol. 113, 52\u201355 (1995).","journal-title":"Arch. Ophthalmol."},{"key":"BFnrendo2010122_CR98","doi-asserted-by":"crossref","unstructured":"[No authors listed] Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group. Diabetes 38, 491\u2013498 (1989).","DOI":"10.2337\/diabetes.38.4.491"},{"key":"BFnrendo2010122_CR99","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0002-9394(99)00362-1","volume":"129","author":"LN Johnson","year":"2000","unstructured":"Johnson, L. N., Stetson, S. W., Krohel, G. B., Cipollo, C. L. & Madsen, R. W. Aspirin use and the prevention of acute ischemic cranial nerve palsy. Am. J. Ophthalmol. 129, 367\u2013371 (2000).","journal-title":"Am. J. Ophthalmol."},{"key":"BFnrendo2010122_CR100","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1001\/archopht.1992.01080150037023","volume":"110","author":"EY Chew","year":"1992","unstructured":"Chew, E. Y.  et al. Aspirin effects on the development of cataracts in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 16. Arch. Ophthalmol. 110, 339\u2013342 (1992).","journal-title":"Arch. Ophthalmol."},{"key":"BFnrendo2010122_CR101","doi-asserted-by":"crossref","unstructured":"[No authors listed] Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 268, 1292\u20131300 (1992).","DOI":"10.1001\/jama.268.10.1292"},{"key":"BFnrendo2010122_CR102","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1096\/fj.01-0707fje","volume":"16","author":"AM Joussen","year":"2002","unstructured":"Joussen, A. M.  et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 16, 438\u2013440 (2002).","journal-title":"FASEB J."},{"key":"BFnrendo2010122_CR103","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2337\/db06-0789","volume":"56","author":"L Zheng","year":"2007","unstructured":"Zheng, L., Howell, S. J., Hatala, D. A., Huang, K. & Kern, T. S. Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes 56, 337\u2013345 (2007).","journal-title":"Diabetes"},{"key":"BFnrendo2010122_CR104","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.2337\/diabetes.54.12.3418","volume":"54","author":"W Sun","year":"2005","unstructured":"Sun, W., Gerhardinger, C., Dagher, Z., Hoehn, T. & Lorenzi, M. Aspirin at low-intermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non-platelet-mediated effects. Diabetes 54, 3418\u20133426 (2005).","journal-title":"Diabetes"},{"key":"BFnrendo2010122_CR105","doi-asserted-by":"crossref","unstructured":"[No authors listed] Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. The TIMAD Study Group. Arch. Ophthalmol. 108, 1577\u20131583 (1990).","DOI":"10.1001\/archopht.1990.01070130079035"},{"key":"BFnrendo2010122_CR106","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0008-4182(00)80126-X","volume":"35","author":"R Superstein","year":"2000","unstructured":"Superstein, R.  et al. Prevalence of ocular hemorrhage in patients receiving warfarin therapy. Can. J. Ophthalmol. 35, 385\u2013389 (2000).","journal-title":"Can. J. Ophthalmol."},{"key":"BFnrendo2010122_CR107","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/sj.eye.6703069","volume":"23","author":"JD Benzimra","year":"2009","unstructured":"Benzimra, J. D.  et al. The Cataract National Dataset electronic multicentre audit of 55,567 operations: antiplatelet and anticoagulant medications. Eye (Lond.) 23, 10\u201316 (2009).","journal-title":"Eye (Lond.)"},{"key":"BFnrendo2010122_CR108","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.thromres.2009.01.007","volume":"124","author":"E Jamula","year":"2009","unstructured":"Jamula, E., Anderson, J. & Douketis, J. D. Safety of continuing warfarin therapy during cataract surgery: a systematic review and meta-analysis. Thromb. Res. 124, 292\u2013299 (2009).","journal-title":"Thromb. Res."},{"key":"BFnrendo2010122_CR109","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/01.iae.0000243033.39301.10","volume":"27","author":"AD Fu","year":"2007","unstructured":"Fu, A. D.  et al. Anticoagulation with warfarin in vitreoretinal surgery. Retina 27, 290\u2013295 (2007).","journal-title":"Retina"},{"key":"BFnrendo2010122_CR110","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1001\/archopht.124.11.1558","volume":"124","author":"PN Dayani","year":"2006","unstructured":"Dayani, P. N. & Grand, M. G. Maintenance of warfarin anticoagulation for patients undergoing vitreoretinal surgery. Arch. Ophthalmol. 124, 1558\u20131565 (2006).","journal-title":"Arch. Ophthalmol."},{"key":"BFnrendo2010122_CR111","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ajo.2007.05.006","volume":"144","author":"PN Dayani","year":"2007","unstructured":"Dayani, P. N., Siddiqi, O. K. & Holekamp, N. M. Safety of intravitreal injections in patients receiving warfarin anticoagulation. Am. J. Ophthalmol. 144, 451\u2013453 (2007).","journal-title":"Am. J. Ophthalmol."},{"key":"BFnrendo2010122_CR112","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/PL00007887","volume":"238","author":"MA Tilanus","year":"2000","unstructured":"Tilanus, M. A., Vaandrager, W., Cuypers, M. H., Verbeek, A. M. & Hoyng, C. B. Relationship between anticoagulant medication and massive intraocular hemorrhage in age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. 238, 482\u2013485 (2000).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"BFnrendo2010122_CR113","doi-asserted-by":"crossref","unstructured":"[No authors listed] Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology 88, 583\u2013600 (1981).","DOI":"10.1016\/S0161-6420(81)34978-1"},{"key":"BFnrendo2010122_CR114","doi-asserted-by":"crossref","unstructured":"[No authors listed] Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 98, 766\u2013785 (1991).","DOI":"10.1016\/S0161-6420(13)38011-7"},{"key":"BFnrendo2010122_CR115","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/00006982-200603000-00016","volume":"26","author":"RL Avery","year":"2006","unstructured":"Avery, R. L. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26, 352\u2013354 (2006).","journal-title":"Retina"},{"key":"BFnrendo2010122_CR116","doi-asserted-by":"crossref","unstructured":"Yoshida, T.  et al. Digoxin inhibits retinal ischemia-induced HIF-1\u03b1 expression and ocular neovascularization. FASEB J. doi:10.1096\/fj.09-145664.","DOI":"10.1096\/fj.09-145664"},{"key":"BFnrendo2010122_CR117","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/MAJ.0b013e3181942f57","volume":"337","author":"MI Khan","year":"2009","unstructured":"Khan, M. I., Chesney, J. A., Laber, D. A. & Miller, D. M. Digitalis, a targeted therapy for cancer? Am. J. Med. Sci. 337, 355\u2013359 (2009).","journal-title":"Am. J. Med. Sci."},{"key":"BFnrendo2010122_CR118","doi-asserted-by":"publisher","first-page":"5778","DOI":"10.1158\/1078-0432.CCR-08-0706","volume":"14","author":"I Prassas","year":"2008","unstructured":"Prassas, I., Paliouras, M., Datti, A. & Diamandis, E. P. High-throughput screening identifies cardiac glycosides as potent inhibitors of human tissue kallikrein expression: implications for cancer therapies. Clin. Cancer Res. 14, 5778\u20135784 (2008).","journal-title":"Clin. Cancer Res."},{"key":"BFnrendo2010122_CR119","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nm1534","volume":"13","author":"BB Gao","year":"2007","unstructured":"Gao, B. B.  et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat. Med. 13, 181\u2013188 (2007).","journal-title":"Nat. Med."},{"key":"BFnrendo2010122_CR120","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1161\/HYPERTENSIONAHA.108.117663","volume":"53","author":"JA Phipps","year":"2009","unstructured":"Phipps, J. A.  et al. Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability. Hypertension 53, 175\u2013181 (2009).","journal-title":"Hypertension"},{"key":"BFnrendo2010122_CR121","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jaci.2007.04.028","volume":"120","author":"L Schneider","year":"2007","unstructured":"Schneider, L., Lumry, W., Vegh, A., Williams, A. H. & Schmalbach, T. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J. Allergy Clin. Immunol. 120, 416\u2013422 (2007).","journal-title":"J. Allergy Clin. Immunol."},{"key":"BFnrendo2010122_CR122","volume-title":"ClinicalTrials.gov Identifier: NCT00969293.","author":"ML Jacques","year":"2010","unstructured":"Jacques, M. L. Study to assess the safety and tolerability of a single administration of FOV2302 (ecallantide) in patients with macular edema associated with central retinal vein occlusion. ClinicalTrials.gov Identifier: NCT00969293. Clinical Trials.gov \n                    [online]\n                    \n                  , (2010)."},{"key":"BFnrendo2010122_CR123","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1056\/NEJMcibr0804551","volume":"359","author":"LP Aiello","year":"2008","unstructured":"Aiello, L. P. Targeting intraocular neovascularization and edema\u2014one drop at a time. N. Engl. J. Med. 359, 967\u2013969 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2010122_CR124","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1056\/NEJMoa041773","volume":"353","author":"D Watanabe","year":"2005","unstructured":"Watanabe, D.  et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N. Engl. J. Med. 353, 782\u2013792 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2010122_CR125","doi-asserted-by":"publisher","first-page":"6998","DOI":"10.1073\/pnas.0800454105","volume":"105","author":"Z Tong","year":"2008","unstructured":"Tong, Z.  et al. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc. Natl Acad. Sci. USA 105, 6998\u20137003 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrendo2010122_CR126","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0140-6736(64)90008-X","volume":"2","author":"ED Powell","year":"1964","unstructured":"Powell, E. D. & Field, R. A. Diabetic retinopathy and rheumatoid arthritis. Lancet 2, 17\u201318 (1964).","journal-title":"Lancet"},{"key":"BFnrendo2010122_CR127","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1752-8062.2008.00026.x","volume":"1","author":"AB Goldfine","year":"2008","unstructured":"Goldfine, A. B.  et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin. Transl. Sci. 1, 36\u201343 (2008).","journal-title":"Clin. Transl. Sci."},{"key":"BFnrendo2010122_CR128","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2337\/dc07-1338","volume":"31","author":"A Fleischman","year":"2008","unstructured":"Fleischman, A., Shoelson, S. E., Bernier, R. & Goldfine, A. B. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 31, 289\u2013294 (2008).","journal-title":"Diabetes Care"},{"key":"BFnrendo2010122_CR129","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/IAE.0b013e3181bcf1a0","volume":"30","author":"EY Chew","year":"2010","unstructured":"Chew, E. Y.  et al. Preliminary assessment of celecoxib and microdiode pulse laser treatment of diabetic macular edema. Retina 30, 459\u2013467 (2010).","journal-title":"Retina"},{"key":"BFnrendo2010122_CR130","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1161\/CIRCULATIONAHA.108.764530","volume":"117","author":"SD Solomon","year":"2008","unstructured":"Solomon, S. D.  et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117, 2104\u20132113 (2008).","journal-title":"Circulation"},{"key":"BFnrendo2010122_CR131","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.ophtha.2007.02.010","volume":"114","author":"E Chew","year":"2007","unstructured":"Chew, E.  et al. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study. Ophthalmology 114, 1190\u20131196 (2007).","journal-title":"Ophthalmology"},{"key":"BFnrendo2010122_CR132","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.ophtha.2006.02.065","volume":"113","author":"MC Gillies","year":"2006","unstructured":"Gillies, M. C.  et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113, 1533\u20131538 (2006).","journal-title":"Ophthalmology"},{"key":"BFnrendo2010122_CR133","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/archopht.121.1.57","volume":"121","author":"JB Jonas","year":"2003","unstructured":"Jonas, J. B., Kreissig, I., Sofker, A. & Degenring, R. F. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch. Ophthalmol. 121, 57\u201361 (2003).","journal-title":"Arch. Ophthalmol."},{"key":"BFnrendo2010122_CR134","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/S0161-6420(02)00975-2","volume":"109","author":"A Martidis","year":"2002","unstructured":"Martidis, A.  et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109, 920\u2013927 (2002).","journal-title":"Ophthalmology"},{"key":"BFnrendo2010122_CR135","doi-asserted-by":"crossref","unstructured":"[No authors listed] A randomized trial comparing intravitreal triamcinolone acetonide and focal\/grid photocoagulation for diabetic macular edema. Ophthalmology 115, 1447\u20131449, 1449.e1\u2013e10 (2008).","DOI":"10.1016\/j.ophtha.2008.06.015"},{"key":"BFnrendo2010122_CR136","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1001\/archophthalmol.2009.109","volume":"127","author":"RW Beck","year":"2009","unstructured":"Beck, R. W.  et al. Three-year follow-up of a randomized trial comparing focal\/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch. Ophthalmol. 127, 245\u2013251 (2009).","journal-title":"Arch. Ophthalmol."},{"key":"BFnrendo2010122_CR137","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1001\/archophthalmol.2009.308","volume":"127","author":"NM Bressler","year":"2009","unstructured":"Bressler, N. M.  et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal\/grid photocoagulation. Arch. Ophthalmol. 127, 1566\u20131571 (2009).","journal-title":"Arch. Ophthalmol."},{"key":"BFnrendo2010122_CR138","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/08820530902800355","volume":"24","author":"PS Silva","year":"2009","unstructured":"Silva, P. S., Sun, J. K. & Aiello, L. P. Role of steroids in the management of diabetic macular edema and proliferative diabetic retinopathy. Semin. Ophthalmol. 24, 93\u201399 (2009).","journal-title":"Semin. Ophthalmol."},{"key":"BFnrendo2010122_CR139","unstructured":"Genentech Inc., Avastin\u00ae (bevacizumab)\u2014Full prescribing information \n                    [online]\n                    \n                  , (2010)."},{"key":"BFnrendo2010122_CR140","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","volume":"36","author":"PJ Rosenfeld","year":"2005","unstructured":"Rosenfeld, P. J., Moshfeghi, A. A. & Puliafito, C. A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg. Lasers Imaging 36, 331\u2013335 (2005).","journal-title":"Ophthalmic Surg. Lasers Imaging"},{"key":"BFnrendo2010122_CR141","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1097\/01.iae.0000247165.38655.bf","volume":"26","author":"C Haritoglou","year":"2006","unstructured":"Haritoglou, C.  et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26, 999\u20131005 (2006).","journal-title":"Retina"},{"key":"BFnrendo2010122_CR142","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00417-008-1034-x","volume":"247","author":"JF Arevalo","year":"2009","unstructured":"Arevalo, J. F.  et al. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefes Arch. Clin. Exp. Ophthalmol. 247, 735\u2013743 (2009).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"BFnrendo2010122_CR143","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/j.ophtha.2006.04.033","volume":"113","author":"DW Chun","year":"2006","unstructured":"Chun, D. W., Heier, J. S., Topping, T. M., Duker, J. S. & Bankert, J. M. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113, 1706\u20131712 (2006).","journal-title":"Ophthalmology"},{"key":"BFnrendo2010122_CR144","volume-title":"ClinicalTrials.gov Identifier: NCT00445003.","author":"RW Beck","year":"2008","unstructured":"Beck, R. W. & Glassman, A. R. Laser-Ranibizumab-Triamcinolone for proliferative diabetic retinopathy (LRTforDME+PRP). ClinicalTrials.gov Identifier: NCT00445003. Clinical Trials.gov \n                    [online]\n                    \n                  , (2008)."},{"key":"BFnrendo2010122_CR145","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.ophtha.2006.08.054","volume":"114","author":"IU Scott","year":"2007","unstructured":"Scott, I. U.  et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114, 1860\u20131867 (2007).","journal-title":"Ophthalmology"},{"key":"BFnrendo2010122_CR146","doi-asserted-by":"crossref","unstructured":"Diabetic Retinopathy Clinical Research Network  et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117, 1064\u20131077 (2010).","DOI":"10.1016\/j.ophtha.2010.02.031"},{"key":"BFnrendo2010122_CR147","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri, S. J.  et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114, 2179\u20132182 (2007).","journal-title":"Ophthalmology"},{"key":"BFnrendo2010122_CR148","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S. & Singh, R. J. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114, 855\u2013859 (2007).","journal-title":"Ophthalmology"},{"key":"BFnrendo2010122_CR149","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/j.ophtha.2006.05.070","volume":"113","author":"AA Moshfeghi","year":"2006","unstructured":"Moshfeghi, A. A.  et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113, 2002\u20132012 (2006).","journal-title":"Ophthalmology"},{"key":"BFnrendo2010122_CR150","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1517\/14712598.5.7.997","volume":"5","author":"MF Mulcahy","year":"2005","unstructured":"Mulcahy, M. F. & Benson, A. B. III. Bevacizumab in the treatment of colorectal cancer. Expert Opin. Biol. Ther. 5, 997\u20131005 (2005).","journal-title":"Expert Opin. Biol. Ther."},{"key":"BFnrendo2010122_CR151","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ophtha.2008.09.046","volume":"116","author":"T Ueta","year":"2009","unstructured":"Ueta, T., Yanagi, Y., Tamaki, Y. & Yamaguchi, T. Cerebrovascular accidents in ranibizumab. Ophthalmology 116, 362 (2009).","journal-title":"Ophthalmology"},{"key":"BFnrendo2010122_CR152","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","volume":"90","author":"AE Fung","year":"2006","unstructured":"Fung, A. E., Rosenfeld, P. J. & Reichel, E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br. J. Ophthalmol. 90, 1344\u20131349 (2006).","journal-title":"Br. J. Ophthalmol."},{"key":"BFnrendo2010122_CR153","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.exer.2009.02.013","volume":"89","author":"J Li","year":"2009","unstructured":"Li, J.  et al. Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes. Exp. Eye Res. 89, 71\u201378 (2009).","journal-title":"Exp. Eye Res."},{"key":"BFnrendo2010122_CR154","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0014-2999(97)01464-7","volume":"341","author":"M Nauck","year":"1998","unstructured":"Nauck, M., Karakiulakis, G., Perruchoud, A. P., Papakonstantinou, E. & Roth, M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur. J. Pharmacol. 341, 309\u2013315 (1998).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrendo2010122_CR155","doi-asserted-by":"publisher","first-page":"10457","DOI":"10.1073\/pnas.92.23.10457","volume":"92","author":"LP Aiello","year":"1995","unstructured":"Aiello, L. P.  et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl Acad. Sci. USA 92, 10457\u201310461 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2010.122","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2010.122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2010.122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:33:55Z","timestamp":1684467235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrendo.2010.122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,27]]},"references-count":155,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["BFnrendo2010122"],"URL":"https:\/\/doi.org\/10.1038\/nrendo.2010.122","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,27]]}}}